|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SETD5 |
Gene summary for SETD5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SETD5 | Gene ID | 55209 |
| Gene name | SET domain containing 5 | |
| Gene Alias | SETD5 | |
| Cytomap | 3p25.3 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q9C0A6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55209 | SETD5 | CCI_1 | Human | Cervix | CC | 8.54e-04 | 6.40e-01 | 0.528 |
| 55209 | SETD5 | CCI_2 | Human | Cervix | CC | 2.17e-09 | 9.68e-01 | 0.5249 |
| 55209 | SETD5 | CCI_3 | Human | Cervix | CC | 3.27e-12 | 9.17e-01 | 0.516 |
| 55209 | SETD5 | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.08e-05 | 5.03e-01 | -0.0811 |
| 55209 | SETD5 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.56e-09 | 5.77e-01 | -0.1954 |
| 55209 | SETD5 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.40e-07 | 6.34e-01 | -0.059 |
| 55209 | SETD5 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.71e-02 | -3.97e-01 | -0.2061 |
| 55209 | SETD5 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.01e-03 | 6.33e-01 | 0.0131 |
| 55209 | SETD5 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.59e-08 | 6.23e-01 | 0.0588 |
| 55209 | SETD5 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.45e-09 | 6.49e-01 | 0.294 |
| 55209 | SETD5 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 8.62e-16 | 1.23e+00 | 0.3487 |
| 55209 | SETD5 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.75e-14 | 7.88e-01 | 0.281 |
| 55209 | SETD5 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.88e-09 | 9.20e-01 | 0.3859 |
| 55209 | SETD5 | F007 | Human | Colorectum | FAP | 1.19e-02 | -2.00e-01 | 0.1176 |
| 55209 | SETD5 | A001-C-207 | Human | Colorectum | FAP | 5.94e-03 | -1.66e-01 | 0.1278 |
| 55209 | SETD5 | A015-C-203 | Human | Colorectum | FAP | 2.92e-36 | -4.04e-01 | -0.1294 |
| 55209 | SETD5 | A015-C-204 | Human | Colorectum | FAP | 2.17e-05 | -1.91e-01 | -0.0228 |
| 55209 | SETD5 | A014-C-040 | Human | Colorectum | FAP | 2.12e-05 | -1.59e-01 | -0.1184 |
| 55209 | SETD5 | A002-C-201 | Human | Colorectum | FAP | 9.70e-14 | -2.93e-01 | 0.0324 |
| 55209 | SETD5 | A001-C-119 | Human | Colorectum | FAP | 3.03e-06 | -3.38e-01 | -0.1557 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00343298 | Cervix | CC | cell junction assembly | 88/2311 | 420/18723 | 3.42e-07 | 1.38e-05 | 88 |
| GO:00063257 | Cervix | CC | chromatin organization | 78/2311 | 409/18723 | 5.40e-05 | 8.02e-04 | 78 |
| GO:00104525 | Cervix | CC | histone H3-K36 methylation | 8/2311 | 15/18723 | 1.53e-04 | 1.85e-03 | 8 |
| GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
| GO:19018886 | Cervix | CC | regulation of cell junction assembly | 42/2311 | 204/18723 | 5.50e-04 | 5.29e-03 | 42 |
| GO:00349685 | Cervix | CC | histone lysine methylation | 27/2311 | 115/18723 | 6.61e-04 | 6.09e-03 | 27 |
| GO:00310565 | Cervix | CC | regulation of histone modification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
| GO:00165715 | Cervix | CC | histone methylation | 30/2311 | 141/18723 | 1.88e-03 | 1.39e-02 | 30 |
| GO:00180224 | Cervix | CC | peptidyl-lysine methylation | 28/2311 | 131/18723 | 2.43e-03 | 1.71e-02 | 28 |
| GO:00064795 | Cervix | CC | protein methylation | 36/2311 | 181/18723 | 2.46e-03 | 1.71e-02 | 36 |
| GO:00082135 | Cervix | CC | protein alkylation | 36/2311 | 181/18723 | 2.46e-03 | 1.71e-02 | 36 |
| GO:00063545 | Cervix | CC | DNA-templated transcription, elongation | 20/2311 | 91/18723 | 6.88e-03 | 3.74e-02 | 20 |
| GO:00182054 | Cervix | CC | peptidyl-lysine modification | 62/2311 | 376/18723 | 1.04e-02 | 4.97e-02 | 62 |
| GO:0034329 | Colorectum | AD | cell junction assembly | 136/3918 | 420/18723 | 2.02e-08 | 1.15e-06 | 136 |
| GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
| GO:1901888 | Colorectum | AD | regulation of cell junction assembly | 61/3918 | 204/18723 | 1.50e-03 | 1.27e-02 | 61 |
| GO:0006354 | Colorectum | AD | DNA-templated transcription, elongation | 31/3918 | 91/18723 | 2.46e-03 | 1.90e-02 | 31 |
| GO:0050808 | Colorectum | AD | synapse organization | 112/3918 | 426/18723 | 4.25e-03 | 2.92e-02 | 112 |
| GO:0010452 | Colorectum | AD | histone H3-K36 methylation | 8/3918 | 15/18723 | 5.67e-03 | 3.64e-02 | 8 |
| GO:0050807 | Colorectum | AD | regulation of synapse organization | 60/3918 | 211/18723 | 5.67e-03 | 3.64e-02 | 60 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SETD5 | SNV | Missense_Mutation | novel | c.572N>G | p.Ser191Cys | p.S191C | Q9C0A6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SETD5 | SNV | Missense_Mutation | c.1130N>T | p.Ser377Phe | p.S377F | Q9C0A6 | protein_coding | deleterious(0.01) | possibly_damaging(0.596) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SETD5 | SNV | Missense_Mutation | c.1853N>A | p.Arg618Gln | p.R618Q | Q9C0A6 | protein_coding | tolerated(0.07) | probably_damaging(0.988) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SETD5 | SNV | Missense_Mutation | novel | c.2798N>T | p.Arg933Ile | p.R933I | Q9C0A6 | protein_coding | tolerated(0.05) | benign(0.202) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SETD5 | SNV | Missense_Mutation | c.2936N>T | p.Thr979Ile | p.T979I | Q9C0A6 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SETD5 | SNV | Missense_Mutation | c.1079N>A | p.Val360Glu | p.V360E | Q9C0A6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | |
| SETD5 | SNV | Missense_Mutation | novel | c.4180N>C | p.Ala1394Pro | p.A1394P | Q9C0A6 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SETD5 | SNV | Missense_Mutation | c.2198C>A | p.Ala733Glu | p.A733E | Q9C0A6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A1AV-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD | |
| SETD5 | SNV | Missense_Mutation | c.3980C>G | p.Ser1327Cys | p.S1327C | Q9C0A6 | protein_coding | deleterious(0) | benign(0.001) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| SETD5 | SNV | Missense_Mutation | c.2377N>G | p.Met793Val | p.M793V | Q9C0A6 | protein_coding | tolerated(0.23) | benign(0.16) | TCGA-BH-A1FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |